Catalyst Biosciences Partners with Wyeth, Deal Could Be Worth $500 Million+
Catalyst Biosciences Inc., a South San Francisco-based developer of engineered proteases, has signed an exclusive worldwide collaboration agreement with Wyeth (NYSE: WYE), related to Factor VIIa products to treat hemophilia and other bleeding conditions. Under terms of the deal, Catalyst will receive a $21 million up-front payment, with the potential to earn over $500 million via research funding and milestone payments. Catalyst previously had raised around $83 million, frfom firms like Burrill & Co., Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corp., Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures.
30 June 2009•3 mins read
